Major depressive disorder (MDD) and treatment-resistant depression (TRD) are expensive problems for employers. A sizeable number of working adults suffer from MDD, which impacts their quality of life and their work productivity. Standard workplace mental health support comprises disease management programs, EAPs and behavioral managed health organizations. However, these solutions may not be adequate to support individuals suffering from TRD. Ketamine-Assisted Therapy (KAT) is currently being utilized as a legal treatment for TRD; research continues to explore the efficacy of KAT when other treatments have failed.